A Phase 1 interventional study of [14C]-Paxalisib Capsule in Healthy, sponsored by Kazia Therapeutics Limited. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by Kazia Therapeutics Limited · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Single-centre, open-label, non-randomised study to assess the mass balance recovery, PK, metabolite profile, and metabolite identification of a single oral dose of 14C labelled paxalisib ([14C] Paxalisib) in healthy male subjects.
Kazia Therapeutics Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be dosed on the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects will remain resident in the clinical unit until 168 h post dose (Day 8) and this may be extended up to a maximum of 48 h (i.e., up to Day 10).
Drug: [14C]-Paxalisib Capsule
Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.
Also known as: Phosphoinositide 3-kinase (PI3K) Inhibitor
To determine the mass balance recovery after a single oral dose of carbon-14 ([14C])-Paxalisib
Mass balance recovery of total radioactivity (TR) in all excreta (urine and faeces): CumAe (amount excreted) and Cum%Ae
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To provide plasma samples for metabolite profiling and structural identification
Collection of plasma samples for metabolite profiling, structural identification, and quantification analysis of paxalisib metabolites
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To provide urine samples for metabolite profiling and structural identification
Collection of urine samples for metabolite profiling, structural identification, and quantification analysis of paxalisib metabolites
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To provide faecal samples for metabolite profiling and structural identification
Collection of faecal samples for metabolite profiling, structural identification, and quantification analysis of paxalisib metabolites
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To determine the routes and rates of elimination of [14C]-Paxalisib
Calculation of Ae, %Ae, CumAe, and Cum%Ae for TR by interval in urine and faeces
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To identify the chemical structure of each metabolite accounting for more than 10% (in plasma) of circulating TR or metabolites in excreta (urine and faeces) that account for more than 10% of the administered radioactive dose
Identification of the chemical structure of each paxalisib metabolite accounting for more than 10% by area under the curve (AUC) of circulating TR in plasma to identify major metabolites, and identification of each metabolite in excreta (urine and faeces) that accounts for more than 10% of the administered radioactive dose
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To explore the Cmax pharmacokinetic (PK) parameter of paxalisib following administration of [14C] Paxalisib
Assessment of the PK of an oral \[14C\]-Paxalisib formulation by measurement of paxalisib in plasma including but not limited to Cmax parameter
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To explore the Tmax pharmacokinetic (PK) parameter of paxalisib following administration of [14C] Paxalisib
Assessment of the PK of an oral \[14C\]-Paxalisib formulation by measurement of paxalisib in plasma including but not limited to Tmax parameter
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To explore the AUC(0-last) and AUC(0-inf) pharmacokinetic (PK) parameter of paxalisib following administration of [14C] Paxalisib
Assessment of the PK of an oral \[14C\]-Paxalisib formulation by measurement of paxalisib in plasma including but not limited to AUC(0-last) and AUC(0-inf) parameter
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To explore the Cmax pharmacokinetic (PK) of TR following administration of [14C] Paxalisib
Assessment of the PK of an oral \[14C\]-Paxalisib formulation by measurement of TR in plasma including but not limited to Cmax parameter
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To explore the Tmax pharmacokinetic (PK) of TR following administration of [14C] Paxalisib
Assessment of the PK of an oral \[14C\]-Paxalisib formulation by measurement of TR in plasma including but not limited to Tmax parameter
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To explore the AUC(0-last) and AUC(0-inf) pharmacokinetic (PK) of TR following administration of [14C] Paxalisib
Assessment of the PK of an oral \[14C\]-Paxalisib formulation by measurement of TR in plasma including but not limited to AUC(0-last) and AUC(0-inf) parameter
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To evaluate the extent of distribution of TR into blood cells
Evaluation of whole blood:plasma concentration ratios for TR
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To provide adverse event (AE) safety information for paxalisib
To provide safety information for paxalisib by assessing adverse events.
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To provide blood pressure vital sign safety information for paxalisib
Measuring and assessing blood pressure in standard clinical units and against reference range.
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To provide heart rate vital sign safety information for paxalisib
Measuring and assessing heart rate in standard clinical units against reference range.
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To provide oral temperature vital sign safety information for paxalisib
Measuring and assessing oral temperature in standard clinical units against reference range.
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To provide respiratory rate vital sign safety information for paxalisib
Measuring and assessing respiratory rate in standard clinical units against reference range .
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To provide electrocardiogram (ECG) safety information for paxalisib
Determination of standard ECG parameters including but not limited to PR interval, QRS duration, in standard clinical units against reference range
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To provide physical examination safety information for paxalisib
Assessment of standard clinical whole-body targeted (symptom-driven) physical examination including but not limited to e.g. general appearance, dermatological
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To provide hematology laboratory safety testing information for paxalisib
Measuring and assessing standard array of hematology parameters (e.g. white blood cell count) in standard clinical unit against reference range.
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To provide clinical chemistry laboratory safety testing information for paxalisib
Measuring and assessing standard array of clinical chemistry parameters (e.g. cholesterol) in standard clinical unit against reference range
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
To assess the urine PK of paxalisib following administration of [14C] Paxalisib
Determination of \[14C\] Paxalisib and calculation of Ae (amount excreted), CumAe (cummulative amount excreted), %Ae (fraction of dose excreted) and Cum%Ae (cummulative fraction of dose excreted) as appropriate for paxalisib in urine
Time frame: Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2021 to primary completion in Mar 2023, 19 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GDC-0084
Kazia Therapeutics Limited